Is there a role for ‘modified VAD’ in the treatment of multiple myeloma?

VAD, (Vincristine, Doxorubicin and Dexamethasone) was initially proposed as a salvage therapy for myeloma patients in whom prior alkylating agent therapy failed, although in recent years VAD has been surpassed by novel combination therapies with new biological agents such as thalidomide (and its der...

Descripción completa

Detalles Bibliográficos
Autores principales: Agazzi, A, Sammassimo, S, Laszlo, D, Liptrott, SJ, Cascio, R, Alietti, A, Rabascio, C, Mancuso, P, Pruneri, G, Martinelli, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223996/
https://www.ncbi.nlm.nih.gov/pubmed/22276003
http://dx.doi.org/10.3332/ecancer.2009.136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223996/
https://www.ncbi.nlm.nih.gov/pubmed/22276003
http://dx.doi.org/10.3332/ecancer.2009.136

Ejemplares similares